ArticleJournal of virology2012
Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection.
Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- The epigenetic-immune-microbiome axis in early life: reprogramming the origins and endotypes of pediatric asthma.Frontiers in immunology · 2026Review
- Modulating cytokine microenvironment during T cell activation induces protective RSV-specific lung resident memory T cells in early life in mice.Npj viruses · 2024Article
- IL-1α is required for T cell-driven weight loss after respiratory viral infection.Mucosal immunology · 2024Article
- The Neonatal Immune System and Respiratory Pathogens.Microorganisms · 2023Review
- Enhanced IL-2 in early life limits the development of TFH and protective antiviral immunity.The Journal of experimental medicine · 2021Article
- Interferon-Induced Transmembrane Protein 1 Restricts Replication of Viruses That Enter Cells via the Plasma Membrane.Journal of virology · 2019Article
- RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.Human vaccines & immunotherapeutics · 2019Article
- Neonatal Immunity, Respiratory Virus Infections, and the Development of Asthma.Frontiers in immunology · 2018Review
- A plasmid containing CpG ODN as vaccine adjuvant against grass carp reovirus in grass carpOncotarget · 2017Article
- Respiratory syncytial virus infection of newborn CX3CR1-deficient mice induces a pathogenic pulmonary innate immune response.JCI insight · 2017Article
- Pulmonary Susceptibility of Neonates to Respiratory Syncytial Virus Infection: A Problem of Innate Immunity?Journal of immunology research · 2017Review
- Innate Immunity to Respiratory Infection in Early Life.Frontiers in immunology · 2017Review
- α-Tocopherol supplementation of allergic female mice inhibits development of CD11c+CD11b+ dendritic cells in utero and allergic inflammation in neonates.American journal of physiology. Lung cellular and molecular physiology · 2014Article
- Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.American journal of respiratory and critical care medicine · 2014Article
- Intramuscular administration of a synthetic CpG-oligodeoxynucleotide modulates functional responses of neutrophils of neonatal foals.PloS one · 2014Article
- Immunity to RSV in Early-Life.Frontiers in immunology · 2014Review
- Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system.Journal of virology · 2014Article
- Monitoring Therapeutic Treatments againstPathogens (Basel, Switzerland) · 2013Article
- Host-Viral Interactions: Role of Pattern Recognition Receptors (PRRs) in Human Pneumovirus Infections.Pathogens (Basel, Switzerland) · 2013Article
- Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Severe respiratory viral infection in early life is associated with recurrent wheeze and asthma in later childhood. Neonatal immune responses tend to be skewed toward T helper 2 (Th2) responses, which may contribute to the development of a pathogenic recall response to respiratory infection. Since neonatal Th2 skewing can be modified by stimulation with Toll-like receptor (TLR) ligands, we investigated the effect of exposure to CpG oligodeoxynucleotides (TLR9 ligands) prior to neonatal respiratory syncytial virus (RSV) infection in mice. CpG preexposure was protective against enhanced disease during secondary adult RSV challenge, with a reduction in viral load and an increase in Th1 responses. A similar Th1 switch and reduction in disease were observed if CpG was administered in the interval between neonatal infection and challenge. In neonates, CpG pretreatment led to a transient increase in expression of major histocompatibility complex class II (MHCII) and CD80 on CD11c-positive cells and gamma interferon (IFN-γ) production by NK cells after RSV infection, suggesting that the protective effects may be mediated by antigen-presenting cells (APC) and NK cells. We conclude that the adverse effects of early-life respiratory viral infection on later lung health might be mitigated by conditions that promote TLR activation in the infant lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.